Pharmaceutical Business Review
Return to: PBR Home | Companies

ImmunoGen Inc

ImmunoGen Inc
830 Winter Street
United States of America
Phone: 1 781 8950600

No. employees: 293
Turnover: 115.45 (US$m)
Financial year end: December

Company Overview

Top Competitors

Key Employees

Stephen C. McCluski

Chairman, Executive Board

Mark J. Enyedy

President, Chief Executive Officer, Director, Executive Board

Dean Mitchell

Director, Non Executive Board

Richard Wallace

Director, Non Executive Board

Daniel M. Junius

Director, Non Executive Board

Joseph J. Villafranca, Ph.D.

Director, Non Executive Board

Mark Goldberg, M.D.

Director, Non Executive Board

Kristine Peterson

Director, Non Executive Board

Stuart A. Arbuckle

Director, Non Executive Board

Thomas Ryll, Ph.D.

Vice President - Technical Operations, Senior Management

Anna Berkenblit, M.D.

Vice President, Chief Medical Officer, Senior Management

Theresa Wingrove, Ph.D.

Senior Vice President - Regulatory Affairs and Quality, Senior Management

David Johnston

Chief Financial Officer, Executive Vice President, Senior Management

Craig Barrows

Secretary, General Counsel, Executive Vice President, Senior Management

Richard J. Gregory, Ph.D.

Executive Vice President - Research, Chief Scientific Officer, Senior Management

Audrey Bergan

Executive Director, Human Resources, Senior Management

Blaine Mckee PhD

Executive Vice President, Chief Business Officer, Senior Management


830 Winter Street,
United States of America
Phone: 1 781 8950600

ImmunoGen Europe Ltd

3rd Floor,
24 Chiswell Street,
Greater London,
United Kingdom

ImmunoGen Securities Corp

Suite 830,
Winter Street,
Waltham ,
United States of America



  • Product Pipeline:
  • Wholly Owned
  • Mirvetuximab Soravtansine, for Platinum-Resistant Ovarian Cancer
  • Coltuximab Ravtansine, for DLBCL
  • IMGN779, for Acute Myeloid Leukemia
  • IMGN632, for Hematologic Malignancies
  • Early Stage Pipeline:
  • ADAM9: MacroGenics Co-Development
  • cMet
  • EpCAM Probody Drug Conjugate
  • Hematologic Malignancies
  • Ovarian Next Generation
  • Exploratory